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Background: Bronchiolitis is the most common reason for hospital admission in infants,
with one third requiring oxygen therapy due to hypoxemia. It is unknown what proportion
of hypoxemic infants with bronchiolitis can be managed with nasal high-flow in room air
and their resulting outcomes.
Objectives and Settings: To assess the effect of nasal high-flow in room air in a
subgroup of infants with bronchiolitis allocated to high-flow therapy in a recent multicenter
randomized controlled trial.
Patients and Interventions: Infants allocated to the high-flow arm of the trial were
initially treated with room air high-flow if saturations were ≥85%. Subsequently, if oxygen
saturations did not increase to ≥92%, oxygen was added and FiO2 was titrated to
increase the oxygen saturations. In this planned sub-study, infants treated during their
entire hospital stay with high-flow room air only were compared to infants receiving either
standard-oxygen or high-flow with oxygen. Baseline characteristics, hospital length of
stay and length of oxygen therapy were compared.
Findings: In the per protocol analysis 64 (10%) of 630 infants commenced on high-
flow room air remained in room air only during the entire stay in hospital. These
infants on high-flow room air were on average older and presented with moderate
hypoxemia at presentation to hospital. Their length of respiratory support and length
of stay was also significantly shorter. No pre-enrolment factors could be identified in a
multivariable analysis.
Franklin et al. High-Flow Room Air in Bronchiolitis
Conclusions: In a small sub-group of hypoxemic infants with bronchiolitis hypoxemia
can be reversed with the application of high-flow in room air only.
Trial registration: ACTRN12615001305516
Keywords: oxygen therapy, room air, bronchiolitis, respiratory illness, nasal high flow therapy
INTRODUCTION
The application of oxygen for hypoxemia represents one of
the most common medical and nursing interventions globally
(1). Traditionally, oxygen was considered a safe intervention,
but an increasing body of evidence demonstrates potential for
harm in acute care settings including perinatal adaptation (2,
3), cardiac arrest (4), and acute stroke (5). Adverse effects
of oxygen may relate to toxicity of free oxygen radicals, and
adaptive mechanisms in health and disease (6–8). As a result,
the application of oxygen as a drug is undergoing more scrutiny.
Furthermore, access to oxygen in remote facilities and in low
income countries can be problematic (9, 10).
The oxygen requirement in acute respiratory diseases leading
to hypoxemia depends on several pathophysiological factors such
as ventilation inhomogeneity, atelectasis, or consolidated lung
parenchyma, an increased intra pulmonary shunt fraction and
decreased alveolar-capillary membrane diffusion capacity (11).
Traditionally, the first approach to improve hypoxemia consisted
in increasing inspired oxygen fraction to treat the symptom
whilst simultaneously searching for the cause of the hypoxemia. If
this approach is ineffective then non-invasive, mainly continuous
positive airway pressure (CPAP) or invasive ventilation strategies
are commonly used in an incremental fashion, though both
are highly resource and skill dependent (12). In contrast to
oxygen alone, alveolar recruitment by provision of CPAP is
likely to reverse or improve many conditions that lead to
hypoxemia in children, whereas restricted oxygen diffusion due
to thickened alveolar-capillary membrane is less commonly a
feature early in the disease process. The application of CPAP
however can be challenging, requires highly trained nursing
and medical staff, is not always tolerated by patients, and
therefore has been in the past restricted to intensive care unit
(ICU) settings.
Nasal high-flow therapy, as a new positive airway pressure
modality has been rapidly adopted in ICU, and subsequently
in emergency departments (EDs) and general wards because
of its ease of use (13–15). Physiological and clinical studies
demonstrate a CPAP effect at high-flow rates that exceed peak
inspiratory flow (16–18).
We recently published the findings of the Pediatric Acute
Respiratory Intervention (PARIS) randomized controlled trial
(RCT), which randomized 1,472 hypoxemic infants with
bronchiolitis to either nasal high-flow therapy or standard-
oxygen therapy with the option to use rescue high-flow if infants
failed standard-oxygen therapy (19). Nested within this RCT we
addressed the pre-planned question whether high-flow therapy
can normalize oxygenation without any increase in the FiO2
provided (20). We hypothesized that high-flow room air is
sufficient to restore adequate oxygenation in a subset of infants
with bronchiolitis presenting with hypoxemia.
METHODS
The protocol, methods, and results of the RCT have been
described previously (19, 20). Briefly, 1,472 infants, <12 months
of age, admitted to 17 hospitals in Australia and New Zealand
with bronchiolitis and an oxygen requirement were randomized
in an open-label study design to treatment with standard
subnasal oxygen or nasal high-flow (20). The primary outcome
for the trial was treatment failure, defined by the presence
of ≥3 of a possible 4 abnormal physiological parameters, and
escalation of care. The trial confirmed that treatment failure and
escalation of care occurred in fewer patients randomized to high-
flow compared with standard-oxygen (p < 0.001). The trial was
undertaken between October 2013 and August 2016, and the
relevant human research ethics committee at each participating
site approved the study (HREC/13/QRCH/93). Informed written
consent was obtained by parent or guardian.
The primary objective of this pre-specified sub-study was to
test if the oxygen requirement can be reversed in infants with
bronchiolitis, by the provision of room air high-flow alone. For
this purpose, the study protocol required that all infants, who
were allocated to the high-flow arm, and with enrolment oxygen
saturation between 85 and ≤92/94%, to be initially commenced
on high-flow room air (FiO2 0.21) at 2 L/kg/min via age-
appropriate Optiflow JuniorTM cannula and Airvo2TM high-flow
system (Fisher & Paykel Healthcare; Auckland, New Zealand).
If high-flow room air had failed to achieve target saturations of
≥92% in participating tertiary children’s hospitals, and ≥94%
in secondary hospitals (saturation targets were set by individual
institution’s standard current practice and not specified centrally
by the trial investigators) after 10min the FiO2 of the high-
flow system was increased to achieve the target saturation. High-
flow room air was stopped (i.e., flow rate reduced from 2 to
0 L/kg/min without gradual reduction) as soon as clinicians
saw clinical improvement and participant’s oxygen saturation
was maintained at ≥92/94% for at least 4 h. For those infants
receiving nasal high-flow oxygen, the FiO2 was titrated to keep
saturations between a 92/94 and 98% target, and once on high-
flow room air for 4 h and maintaining target saturations, high-
flow therapy was stopped. If infants subsequently developed
a further oxygen requirement, according to their institution’s
definition, high-flow was instigated using the same procedures as
at initiation of high-flow at randomization. Infants allocated to
standard-oxygen therapy received 100% subnasal oxygen up to a
maximum of 2 L/min to maintain oxygen saturations within the
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FIGURE 1 | Oxygen treatment group allocation.
same targets as the high-flow arm. All other bronchiolitis specific
therapies were at the discretion of the treating clinician.
Oxygen Therapy Groups (Figure 1)
We defined four oxygen therapy groups for this sub-study.
Infants allocated to standard-oxygen remained on subnasal
standard-oxygen (standard-oxygen group) unless they required
escalation of care, which in most of these infants was achieved by
using high-flow with oxygen. Infants allocated to high-flow with
saturations <85% at randomization received immediate high-
flow with oxygen (high-flow with immediate oxygen group).
The threshold of 85% was chosen in consensus with the
participating hospitals. Infants allocated to high-flow presenting
with saturations between 85 and ≤92/94% were started on high-
flow room air. Infants without improved oxygenation (saturation
≤92/94%) after 10min on high-flow room air were switched to
high-flow with oxygen (high-flow with oxygen group) whereas
infants who improved their saturations to≥92/94% remained on
high-flow room air (high-flow room air group).
Study Outcomes
The primary outcomes were: first a proof of concept to
demonstrate whether a subgroup of hypoxemic infants with
bronchiolitis can be treated with high-flow room air only while
maintaining their target saturations; and secondly to determine
the proportion of hypoxemic infants with bronchiolitis that
respond to high-flow in room air. Secondary outcomes
included differences in basic demographics, risk factors such as
prematurity and pre-existing disease, virus detected, severity of
disease at randomization, length of hospital stay, and length
of high-flow therapy. The physiological response of heart and
respiratory rate to high-flow room air was analyzed for the first
3 days of admission. In one of the participating hospitals all data
on the change of respiratory and heart rate, and saturation of all
infants enrolled were also obtained relating to the first hour of
oxygen therapy post start of the intervention (Table 2).
The sub-group of infants receiving high-flow room air only
were compared to the three oxygen groups; infants on standard
oxygen, infants on high-flow with immediate oxygen, and infants
high-flow with oxygen.
Statistical Analysis
The sample size of 1,400 infants for the RCT was based on a
50% reduction in failure rate of oxygen therapy at 90% power
and type I error of 0.05. Allocation to treatment arm was as the
per protocol analysis. Continuous data are presented as mean
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TABLE 1 | Pre-enrolment characteristics.
Pre-enrolment characteristic Treatment group p-value
Standard-oxygen High-flow with
immediate oxygen
High-flow with
oxygen
High-flow room air
N = 710 N = 52 N = 630 N = 64
Age (months)∧ 6.3 (6.1) 3.5 (6.6) 5.8 (6.3) 5.9 (4.5) 0.001
Age (months) ≤3 months 180 (25.4) 24 (46.2) 180 (28.6) 11 (17.2) 0.002
>3–6 months 160 (22.5) 13 (25.0) 154 (24.4) 22 (34.4)
>6 months 370 (52.1) 15 (28.9) 296 (47.0) 31 (48.4)
Weight (kg)# 7.62 (2.22) 6.45 (2.39) 7.27 (2.24) 7.46 (1.96)* <0.001
Sex Female 252 (35.5) 17 (32.7) 251 (39.8) 22 (34.4) 0.339
Ethnicity Caucasian 370 (52.1) 20 (38.5) 343 (54.4) 29 (45.3) 0.213
Aboriginal/Torres
Strait Islander
29 (4.1) 2 (3.9) 24 (3.8) 3 (4.7)
Maori/Pacific Islander 213 (30.0) 18 (34.6) 157 (24.9) 22 (34.4)
Other/unknown 98 (13.8) 12 (23.1) 157 (24.9) 10 (15.6)
Risk factors Prematurity <37
weeks
123 (17.3) 11 (21.2) 118 (18.6) 11 (17.2) 0.840
Previous need for
neonatal respiratory
support
101 (14.2) 11 (21.2) 93 (14.8) 11 (17.2) 0.506
Oxygen only 36 (5.1) 3 (5.8) 24 (3.8) 3 (4.7) 0.608
CPAP/NIV 70 (9.9) 8 (15.4) 60 (9.5) 8 (12.5) 0.454
Invasive ventilation 19 (2.7) 3 (5.8) 21 (3.3) 5 (7.8) 0.087
Other respiratory
support
12 (1.7) 3 (5.8) 19 (3.0) 3 (4.7) 0.059
Previous hospital
admissions for
respiratory disease
postnatal
217 (30.6) 14 (26.9) 160 (25.4) 14 (21.9) 0.140
Previous ICU
admission for
respiratory support
46 (6.5) 2 (3.9) 21 (3.3) 3 (4.7) 0.057
Intubated & ventilated 7 (1.0) 0 (0.0) 4 (0.6) 0 (0.0) 0.822
Mask ventilation 6 (0.9) 0 (0.0) 2 (0.3) 0 (0.0) 0.638
High-flow therapy 35 (4.9) 2 (3.9) 15 (2.4) 2 (3.1) 0.081
Chronic Lung
Disease
12 (1.7) 0 (0.0) 14 (2.2) 3 (4.7) 0.273
Congenital Heart
Disease
16 (2.3) 0 (0.0) 8 (1.3) 0 (0.0) 0.391
Patient history of
wheeze
174 (24.7) 9 (17.3) 133 (21.3) 15 (23.8) 0.377
Family history of
asthma
349 (49.9) 17 (32.7) 286 (46.4) 31 (50.8) 0.082
Family history of
allergy
159 (22.8) 8 (15.4) 111 (18.0) 14 (23.0) 0.130
Currently attending
child care?
91 (13.2) 6 (11.5) 77 (12.8) 11 (18.0) 0.671
Viral etiology Number tested N = 564 N = 41 N = 536 N = 45 –
Respiratory syncytial
virus
309 (54.8) 30 (73.2) 287 (53.5) 25 (55.6) 0.110
Other viruses 194 (34.4) 11 (26.8) 155 (28.9) 14 (31.1) 0.241
Multiple viruses 106 (18.8) 10 (24.4) 86 (16.0) 9 (20.0) 0.372
No virus detected on
nasopharyngeal
aspirate
108 (19.2) 5 (12.2) 134 (25.0) 11 (24.4) 0.047
(Continued)
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TABLE 1 | Continued
Pre-enrolment characteristic Treatment group p-value
Standard-oxygen High-flow with
immediate oxygen
High-flow with
oxygen
High-flow room air
Non study treatments
received
Any non-study
treatments received
510 (71.8) 46 (88.5)* 410 (65.1) 44 (68.8) 0.001
Steroids 59 (8.3) 1 (1.9) 50 (7.9) 1 (1.6) 0.089
Nebulized Saline 87 (12.3) 7 (13.5) 70 (11.1) 3 (4.7) 0.281
Bronchodilators 211 (29.7) 12 (23.1) 158 (25.1) 10 (15.6) 0.036
Adrenaline
nebulizations
2 (0.3) 1 (1.9) 5 (0.8) 0 (0.0) 0.211
Antibiotics 115 (16.2)* 20 (38.5)*** 95 (15.1)* 4 (6.3) <0.001
Pain/fever 266 (37.5) 32 (61.5) 210 (33.3) 30 (46.9) <0.001
Sedation 35 (4.9) 8 (15.4)** 40 (6.4) 1 (1.6) 0.013
Time of onset of
illness to presentation
in days∧
3 (2) 3 (2) 3 (2) 3 (3) 0.645
∧Median (interquartile range); #Mean (standard deviation); *p < 0.05; **p < 0.01; ***p < 0.001 in comparison to group 4 (high-flow room air group).
and standard deviation (SD) or median and interquartile range
(IQR) dependent on variable distribution; categorical data are
presented using number and percentage. Comparisons between
the treatment groups were made using ANOVA, Kruskal–
Wallis or Fisher’s exact tests; following a significant p-value
(<0.05) post-hoc comparisons were undertaken comparing the
in-room air group to the other treatment groups (adjustment
using Bonferroni’s correction). Further analysis was undertaken
comparing high-flow in room air vs. a combined group of
standard-oxygen and high-flow with oxygen. Bivariable analysis
was initially undertaken and variables with a p< 0.25 remained in
the multivariable model. Comparison of infants in the standard
oxygen group presenting with pre-enrolment saturations <85%
to infants with saturations between 85 and ≤92/94% were
undertaken using t-tests, Mann–Whitney U-test and Fisher’s
exact test. Analyses were conducted in StataIC version 14.1
(StataCorp LP, College Station, Texas).
RESULTS
In the original RCT, 1,472 infants with bronchiolitis were
randomized and subsequently provided written consent; in the
per protocol analysis 710 received standard-oxygen and 746
received high-flow of which 52 (7%) commenced on high-flow
with immediate oxygen, 630 (70%) commenced high-flow room
air with a later increase of FiO2 and 64 (9%) received high-flow
room air (Figure 1). Table 1 shows the baseline characteristics of
the infants in high-flow room air compared to infants on high-
flow with immediate oxygen, high-flow with oxygen and infants
treated with standard-oxygen therapy. There were a number
of statistical differences in several of the pre-enrolment factors
between the three study groups (Table 1): the distribution of age
at enrolment was significantly different between the treatment
groups with the proportion of infants <3 months of age lowest
in the high-flow room air (17.2%), the body weight was highest
in the high-flow room air group, followed by the standard-
oxygen group and then high-flow in oxygen. Infants on high-
flow with immediate oxygen received more frequently antibiotics
and sedation. Infants in the high-flow room air group showed
higher oxygen saturation pre-enrolment than infants in the other
groups (Table 2). In the cohort of infants (n = 334) in which
physiological parameters were measured within the first hour
of treatment, infants on standard-oxygen showed the highest
saturations. The changes in saturation, heart and respiratory rate
in infants on high-flow room air are shown for the first 72 h
in Figures 2, 3.
The length of hospital stay was shortest in infants in the high-
flow room air group (Table 2). None of the tested pre-enrolment
factors such as age, prematurity, RSV, time of onset of disease to
presentation or heart nor respiratory rate were predictive for a
success of high-flow room air therapy (Table 3).
None of the infants on high-flow room air required intensive
care admission and no adverse events were observed in either the
high-flow room air group or those who commenced treatment
initially in room air.
For completeness, infants in the standard-oxygen group
presenting with pre-enrolment saturations<85%were compared
to infants with saturations between 85 and ≤92/94% and the
comparison is shown in Table 4. Similarly, to the high-flow
group, infants in the standard-oxygen arm presenting with
pre-enrolment saturations of <85% were younger and had
lower body weight. The infants in the standard-oxygen group
and presenting with saturations <85% received similarly to
the patients in the high-flow with immediate oxygen group,
significantly more antibiotics and sedation.
DISCUSSION
The World Health Organization recommended in 2012 that
effective oxygen delivery systems should be a universal standard
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TABLE 2 | Change in physiological parameters as a treatment response to oxygen therapy.
Timepoint Parameter Treatment group p-value
Standard-oxygen High-flow with immediate oxygen High-flow with oxygen High-flow room air
N = 710 N = 52 N = 630 N = 64
Pre-enrolment Heart rate# 161.8 (22.1) [700] 165.8 (23.9) [52] 162.8 (21.1) [620] 162.1 (20.6) [63] 0.544
Respiratory rate# 52.7 (12.1) [694] 57.3 (14.0) [52] 53.8 (11.5) [618] 50.4 (10.4) [63] 0.005
SpO2
∧ 89.0 (3.0) [706] 82.0 (5.5) [52]*** 89.0 (3.0) [624]** 90.0 (3.0) [64] <0.001
Post-enrolment (within 1 h) Heart rate# 163.2 (21.6) [165] 169.5 [30.4] [20] 164.2 [19.4] [149] 153.3 (23.5) [18] 0.120
Respiratory rate# 49.9 (10.5) [161] 58.8 (15.0) [19] 52.2 (10.4) [145] 47.3 (11.5) [18]
SpO2
∧ 98.0 (4.0) [165]*** 95.0 (3.0) [20] 95.0 (5.0) [147] 95.0 (2.0) [17] <0.001
Difference (post-pre) Heart rate# −4.6 (21.7) [156] −3.8 (12.2) [20] −3.0 (19.4) [141] −10.1 (18.0) [17] 0.573
Respiratory rate# −3.8 (10.9) [151] −3.2 (10.0) [19] −2.2 (11.0) [137] −0.5 (13.9) [17] 0.504
SpO2
∧ 9.0 (5.0) [161]*** 14.0 (8.0) [20]*** 6.0 (6.0) [141] 6.0 (4.0) [17] <0.001
Length of hospital stay 2.21 (2.05) [710]*** 3.97 (2.37) [52]*** 2.55 (2.11) [630]*** 1.55 (0.98) [64] <0.001
∧Median (interquartile range) [N]; #Mean (standard deviation) [N]; *p < 0.05; **p < 0.01; ***p < 0.001 in comparison to group 4 (high-flow room air group).
FIGURE 2 | Measured transcutaneous saturation of oxygen levels in 64 infants treated with room air high-flow. Observations were taken initially after 2 h and then
every 4 h.
of care and should be made more widely available (21). At the
same time, an increasing body of evidence suggests potential
for harm related to oxygen application in various settings
including perinatal adaptation, cardiac arrest, and intensive care
(2–5). Furthermore, in adults receiving mechanical ventilation
it has been shown that a large number of patients were left
on unnecessarily high inspired oxygen fraction, which can
contribute to lung disease (22). Bronchiolitis represents the most
common disease leading to non-elective admission of infants
and oxygen remains the mainstay of therapy for this patient
group (23). Our data demonstrates that in a small subgroup of
hypoxemic infants with bronchiolitis the oxygen requirement
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FIGURE 3 | (A,B) Measured heart and respiratory rate in 64 infants treated with high-flow in room air. Observations were taken initially after 2 h and then every 4 h.
Mean and 95% confidence interval are indicated.
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TABLE 3 | Multivariable analysis.
Characteristic Bivariable analysis Multivariable analysis
Odds ratio 95% CI p-value Odds ratio 95% CI p-value
Age (months) ≤3 months 0.66 0.33, 1.32 0.238 0.73 0.36, 1.47 0.372
>3–6 months 1.51 0.86, 2.64 0.154 1.62 0.92, 2.87 0.095
>6 months (reference group) 1 – – 1 – –
Risk Factors Prematurity <37 weeks 0.95 0.49, 1.85 0.881 – – –
Respiratory syncytial virus 0.80 0.48, 1.34 0.395 – – –
Time of onset of illness to presentation (days) (log-transformed) 0.83 0.57, 1.21 0.341 - – –
Pre-enrolment HR 1.00 0.99, 1.01 0.954 – – –
RR 0.98 0.96, 1.00 0.062 0.98 0.96, 1.00 0.079
can be safely treated with high-flow in room air for their entire
hospital stay. Infants responding to high-flow room air not only
showed a significant improvement in their saturations but also
a reduction in heart and respiratory rates indicating effective
respiratory support (Figures 2, 3). The reversal of the hypoxemia
was likely due to the positive airway pressure effect generated
by nasal high-flow therapy, which improved the underlying
pathophysiology such as ventilation maldistribution and loss of
lung volume (atelectasis). Previous physiological studies have
shown that high-flow rates at 2 L/kg/min generate a positive
airway pressure in the range of 4–6 cm H2O, which can restore
the patient’s functional residual capacity and reduce ventilation
inhomogeneity (24, 25).
The current recommendations for first line treatment of
hypoxemia is the provision of oxygen (26). If supplemental
oxygen is ineffective, then as a second line treatment some form
of positive pressure ventilation either non-invasive or invasive
ventilation should be used. The study design and outcomes in the
high-flow arm suggests it is safe to initially institute high-flow in
room air and to subsequently supplement oxygen in those who
need it, except in infants with severe hypoxemia on presentation
(saturation <85%). The results of this prospective trial indicate
that a small proportion of infants (10%) will respond to high-flow
room air alone, and those requiring oxygen can be safely titrated
to the appropriate dose. Albeit a small proportion of infants in
our study cohort responded to high-flow room air, these findings
provide as a first interesting physiological proof of concept that in
these infants oxygenation can be improved by providing positive
airway pressure only.
A multivariate analysis did not demonstrate any predictive
factors for responders of this approach. Infants who required
high-flow room air only had a significantly shorter stay in
hospital, most likely as a result of a milder form of the
respiratory disease.
The results of our study serve as a proof of concept that may
inform future clinical trials particularly in less well-resourced
settings where access to oxygen is limited. This could prove
beneficial for regions where the mortality of infants with
chest infections and an oxygen requirement is 8% (African
FEAST trial) (27, 28). A recent study in Bangladesh compared
standard-oxygen, bubble CPAP, and high-flow in children with
chest infections aged up to 5 years. The median saturation at
presentation in this study was 86 % (IQR 82–88) with only 14% of
enrolled children having a saturation of <85% (29). The current
COAST trial being performed in Uganda and Kenya in children
presenting with a chest infection and an oxygen requirement
is currently investigating if high-flow in room air can reverse
hypoxemia and reduce mortality (28).
One of the shifts in paradigm in this study was that oxygen
therapy was started from “low”—in room air—and titrated up to
reach the desired SpO2 threshold >92/94% whereas traditionally
oxygen therapy was introduced from “high” to achieve maximal
saturations and then titrated down. It is likely that the titrate up
strategy will mean that saturation levels will be maintained closer
to the lower acceptable levels than in the titrate down strategy.
Hyperoxia is commonly observed in mechanically ventilated
patients and most often related to the reluctance of clinicians to
reduce the inspired oxygen fraction (22). In the small cohort of
infants in whom physiological parameters were also measured
within the first hour of treatment, the oxygen saturations were
highest in the standard-oxygen group. In the high-flow group the
clinicians were instructed to start with low FiO2 (room air) and
only increase if required, whereas in the standard-oxygen group
no instructions were given.
Limitations
The medical records in the participating sites did not allow
measuring the fidelity if clinicians strictly adhered to the
proposed high-flow room air approach, hence the proportion of
patients who would have benefitted from the high-flow room
air approach may have been greater. Our study protocol used a
saturation target between 92 and 98% (in some centers 94–98%).
WHO is recommending a lower threshold of 90% to initiate
oxygen therapy. Therefore, using a lower treatment threshold
for hypoxemia would have likely increased the proportion of
successful treatments with high-flow in room air. A recent study
in bronchiolitis in the UK showed that keeping a threshold
of 90% compared to 94% did not impact on safety and
efficacy (30).
CONCLUSION
A small proportion of infants with bronchiolitis and hypoxemia
who were admitted to hospital did respond to nasal high-flow
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TABLE 4 | Comparison of those treated with standard-oxygen <85% and ≥85%.
Pre-enrolment characteristic Standard oxygen p-value
SpO2 < 85% SpO2 ≥ 85%
N = 43 N = 669
Age (months)∧ 4.9 (6.6) 6.4 (5.9) 0.029
Age (months) ≤3 months 18 (43.9) 162 (24.2) 0.024
>3–6 months 8 (19.5) 152 (22.7)
>6 months 15 (36.6) 355 (53.1)
Weight (kg)# 6.7 (2.6) 7.7 (2.2) 0.004
Sex Female 11 (26.8) 241 (36.0) 0.313
Ethnicity Caucasian 18 (43.9) 352 (52.6) 0.464
Aboriginal/Torres Strait Islander 1 (2.4) 28 (4.2)
Maori/Pacific Islander 17 (41.5) 196 (29.3)
Other/unknown 5 (12.2) 93 (13.9)
Risk factors Prematurity <37 weeks 11 (26.8) 112 (16.7) 0.133
Previous need for neonatal respiratory support 5 (12.2) 96 (14.4) 0.821
Oxygen only 2 (4.9) 34 (5.1) 0.999
CPAP/NIV 4 (9.8) 66 (9.9) 0.999
Invasive ventilation 0 (0.0) 19 (2.8) 0.619
Other respiratory support 1 (2.4) 11 (1.6) 0.513
Previous hospital admissions for respiratory disease postnatal 14 (34.2) 203 (30.3) 0.603
Previous ICU admission for respiratory support 2 (4.9) 44 (6.6) 0.999
Intubated & ventilated 0 (0.0) 7 (1.1) 0.999
Mask ventilation 0 (0.0) 6 (0.9) 0.999
High-flow therapy 2 (4.9) 33 (4.9) 0.999
Chronic Lung Disease 1 (2.4) 11 (1.7) 0.514
Congenital Heart Disease 2 (4.9) 14 (2.1) 0.236
Patient history of wheeze 9 (22.0) 165 (24.8) 0.852
Family history of asthma 14 (34.2) 335 (50.9) 0.052
Family history of allergy 10 (25.0) 149 (22.7) 0.701
Currently attending child care? 2 (5.0) 89 (13.7) 0.148
Viral etiology Number tested N = 32 N = 532
Respiratory syncytial virus 22 (68.8) 287 (54.0) 0.142
Other viruses 11 (34.4) 183 (34.4) 0.999
Multiple viruses 9 (28.1) 97 (18.2) 0.166
No virus detected on nasopharyngeal aspirate 1 (3.1) 107 (20.1) 0.018
Non study treatments received Any non-study treatments received 29 (70.7) 481 (71.9) 0.859
Steroids 1 (2.4) 58 (8.7) 0.242
Nebulized Saline 4 (9.8) 83 (12.4) 0.807
Bronchodilators 9 (22.0) 202 (30.2) 0.296
Adrenaline nebulizations 0 (0.0) 2 (0.3) 0.999
Antibiotics 15 (36.6) 100 (15.0) 0.001
Pain/fever 18 (43.9) 248 (37.1) 0.408
Sedation 5 (12.2) 30 (4.5) 0.045
Time of onset of illness to presentation in days∧ 3 (3) 3 (2) 0.624
∧Median (interquartile range); #Mean (standard deviation).
therapy using room air only. The clinical improvement of
the high-flow therapy could be demonstrated immediately
with decreased heart and respiratory rate. Nasal high-
flow room air therapy may be a valuable option to treat
hypoxemia in bronchiolitis in settings with limited access
to oxygen.
EVIDENCE BEFORE THIS STUDY
A comprehensive literature search using MEDLINE, Cochrane,
CINAHL, and EMBASE demonstrated that high-flow therapy has
clinical benefit over standard oxygen therapy used in infants with
bronchiolitis in general ward settings with two large randomized
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controlled trials showing a reduced need to escalate therapy. No
study could be identified to investigate the role of high-flow in
room air and its clinical effect.
ADDED VALUE OF THIS STUDY
The study findings are a proof of concept. The results may
instigate new trials using high-flow in room air in settings with
limited access to oxygen supplies.
IMPLICATIONS OF ALL THE AVAILABLE
EVIDENCE
This study presents as a first a novel concept to improve
hypoxemia in infants with bronchiolitis. The approach is
to first apply positive airway pressure support followed by
increasing the oxygen fraction if required. Titration of oxygen
from low to normal saturation as a mean to limit possible
oxygen toxicity.
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